You are here: Industry Insights > Market News > Japan studying giving third COVID-19 shots next year

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

3-Bromo-4-fluorobenzaldehyde

5-Methyl-1,3,4-oxadiazol2(3H)-one

4-Amino-6-methyl-3 oxo2,3, 4,5-tetrahydro 1.2.4-triazine hydrochloride

4-Acetylamino-6-methyl -3-oxo-2,3,4,5-tetrahydro-1,2,4-triazine

3-Pyridinecarboxaldehyde

Ethyl 3 Fluorobenzoate

Japan studying giving third COVID-19 shots next year

firstwordpharmaAugust 09, 2021

Tag: COVID-19 , Vaccine , Moderna

Favorites

Japan has begun a study on whether it should administer third doses of COVID-19 vaccines next year, as reported The Japan Times.

The government will proceed with the study while trying to secure the supply of at least 200 million doses next year, officials said.

Japan studying giving third COVID-19 shots next year

Taro Kono, the minister in charge of vaccination efforts, has said that Japan "will likely administer next year" third doses of the COVID-19 vaccine.

In July, the government struck a contract to receive an additional 50 million doses of Moderna's vaccine from the beginning of 2022, and discussions are under way to secure 150 million doses of the vaccine developed by Novavax starting in early 2022.

Previous:FDA to allow export of certain lots of AstraZeneca COVID-19 vaccine made at Baltimore plant

Next:JCVI ‘largely opposed’ to Covid vaccination for children under 16

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

PharmaSourcesNovember 22, 2024

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, today opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts.

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

Japan studying giving third COVID-19 shots next year | Pharmasources.com

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

You may like
More>>

International standard Group ACYW135 Meningococcal Polysaccharide Vaccine with lower adverse effect

Hualan Biological Influenza Vaccine

Influenza Vaccine(Split Virion),Inactivated with good safety

Influenza A (H1N1) Vaccine, (Split, Inactivated)by Hualan biological 1

High-dose trivalent influenza vaccine

Good immunogenicity performance Influenza Vaccine (Split virion)

Quadrivalent Influenza Vaccine, Inactivated

Hualan Biological Recombinant Hepatitis B Vaccine (Hansenula polymorpha)with High purity and good s

*trivalent flu vaccine

Hualan's Group ACYW135 Meningococcal Polysaccharide Vaccine

Japan studying giving third COVID-19 shots next year

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

You may likeMore>>

You may like
More>>